Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8891319 | 0.88 | HTR2A (0.54) | HTR2CHTR2AHTR2B | |
| SCHEMBL8890619 | 0.78 | HTR2A (0.50) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL8332736 | 0.78 | HTR2C (0.49) | HTR2CHTR2AHTR2BDRD2CHRM2 | |
| SCHEMBL8330683 | 0.78 | HTR2A (0.49) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL8331305 | 0.78 | HTR2A (0.46) | HTR2CHTR2AHTR2BDRD2CHRM2 | |
| SCHEMBL15767672 | 0.77 | SIGMAR1 (0.45) | HTR2CKDM1ARCOR1 | |
| SCHEMBL23995531 | 0.76 | HTR2C (0.74) | HTR2CHTR2AHTR2BDRD2CHRM2 | |
| SCHEMBL22334915 | 0.76 | HTR2C (0.74) | HTR2CHTR2AHTR2BDRD2CHRM2 | |
| SCHEMBL20205056 | 0.76 | HTR2C (0.74) | HTR2CHTR2AHTR2BDRD2CHRM2 | |
| SCHEMBL8332882 | 0.76 | HTR2A (0.47) | HTR2CHTR2AHTR2BDRD2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5594034-A | ADMINISTERING DIRECT ACTING 5-HYDROXYTRYPTAMINE AGONIST TO MAMMAL | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5594025-A | Method of inhibiting gastric acid secretion with 5-substituted-3-aminochromane | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | disclosed |
| US-5576352-A | Method of inhibiting gastric acid secretion with aryloxypropanolamines | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| US-5457120-A | Antisecretory and antiserotonine agents | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
| US-5340838-A | Administering serotonin agonist to mammals | ELI LILLY AND COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| US-5258379-A | ADMINISTERING IN AN EFFECTIVE DOSAGE TO MAMMALS | ELI LILLY AND COMPANY (US) | 1993-11-02 | — | — | US | disclosed |
| US-5158956-A | Administering serotonin receptor agonist | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| US-5096908-A | 5-HT1A agonist | ELI LILLY AND COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |